Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves
Author
Abstract
Suggested Citation
DOI: 10.1177/0272989X17706081
Download full text from publisher
References listed on IDEAS
- Weinstein, M.C. & Coxson, P.G. & Williams, L.W. & Pass, T.M. & Stason, W.B. & Goldman, L., 1987. "Forecasting coronary heart disease incidence, mortality, and cost: The coronary heart disease policy model," American Journal of Public Health, American Public Health Association, vol. 77(11), pages 1417-1426.
- Natasha Stout & Sue Goldie, 2008. "Keeping the noise down: common random numbers for disease simulation modeling," Health Care Management Science, Springer, vol. 11(4), pages 399-406, December.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- David D. Kim & Lu Wang & Brianna N. Lauren & Junxiu Liu & Matti Marklund & Yujin Lee & Renata Micha & Dariush Mozaffarian & John B. Wong, 2023. "Development and Validation of the US Diabetes, Obesity, Cardiovascular Disease Microsimulation (DOC-M) Model: Health Disparity and Economic Impact Model," Medical Decision Making, , vol. 43(7-8), pages 930-948, October.
- Duncan Ermini Leaf & Bryan Tysinger & Dana P. Goldman & Darius N. Lakdawalla, 2021. "Predicting quantity and quality of life with the Future Elderly Model," Health Economics, John Wiley & Sons, Ltd., vol. 30(S1), pages 52-79, November.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- William S. Weintraub & Samuel S. Gidding, 2016. "PCSK9 Inhibitors: A Technology Worth Paying For?," PharmacoEconomics, Springer, vol. 34(3), pages 217-220, March.
- González-Parra, Gilberto & Villanueva-Oller, Javier & Navarro-González, F.J. & Ceberio, Josu & Luebben, Giulia, 2024. "A network-based model to assess vaccination strategies for the COVID-19 pandemic by using Bayesian optimization," Chaos, Solitons & Fractals, Elsevier, vol. 181(C).
- Michael F. Drummond;Adrian Towse, 1998. "From Efficacy to Cost-Effectiveness," Briefing 000438, Office of Health Economics.
- Yizhe Xu & Tom H. Greene & Adam P. Bress & Brian C. Sauer & Brandon K. Bellows & Yue Zhang & William S. Weintraub & Andrew E. Moran & Jincheng Shen, 2022. "Estimating the optimal individualized treatment rule from a cost‐effectiveness perspective," Biometrics, The International Biometric Society, vol. 78(1), pages 337-351, March.
- Mark Roberts & Louise B. Russell & A. David Paltiel & Michael Chambers & Phil McEwan & Murray Krahn, 2012. "Conceptualizing a Model," Medical Decision Making, , vol. 32(5), pages 678-689, September.
- Gary A. Zarkin & Laura J. Dunlap & Katherine A. Hicks & Daniel Mamo, 2005. "Benefits and costs of methadone treatment: results from a lifetime simulation model," Health Economics, John Wiley & Sons, Ltd., vol. 14(11), pages 1133-1150, November.
- Meltzer, David, 1997. "Accounting for future costs in medical cost-effectiveness analysis," Journal of Health Economics, Elsevier, vol. 16(1), pages 33-64, February.
- Troost, Christian & Huber, Robert & Bell, Andrew R. & van Delden, Hedwig & Filatova, Tatiana & Le, Quang Bao & Lippe, Melvin & Niamir, Leila & Polhill, J. Gareth & Sun, Zhanli & Berger, Thomas, 2023. "How to keep it adequate: A protocol for ensuring validity in agent-based simulation," EconStor Open Access Articles and Book Chapters, ZBW - Leibniz Information Centre for Economics, vol. 159, pages 1-21.
- repec:ijm:journl:v109:y:2017:i:1:p:167-200 is not listed on IDEAS
- K Cooper & S C Brailsford & R Davies, 2007. "Choice of modelling technique for evaluating health care interventions," Journal of the Operational Research Society, Palgrave Macmillan;The OR Society, vol. 58(2), pages 168-176, February.
- Tekeshe A Mekonnen & Michelle C Odden & Pamela G Coxson & David Guzman & James Lightwood & Y Claire Wang & Kirsten Bibbins-Domingo, 2013. "Health Benefits of Reducing Sugar-Sweetened Beverage Intake in High Risk Populations of California: Results from the Cardiovascular Disease (CVD) Policy Model," PLOS ONE, Public Library of Science, vol. 8(12), pages 1-9, December.
- Karen T. Hicklin & Julie S. Ivy & James R. Wilson & Fay Cobb Payton & Meera Viswanathan & Evan R. Myers, 2019. "Simulation model of the relationship between cesarean section rates and labor duration," Health Care Management Science, Springer, vol. 22(4), pages 635-657, December.
- Davies, Ruth & Roderick, Paul & Raftery, James, 2003. "The evaluation of disease prevention and treatment using simulation models," European Journal of Operational Research, Elsevier, vol. 150(1), pages 53-66, October.
- K. Cooper & S. Brailsford & R. Davies & J. Raftery, 2006. "A review of health care models for coronary heart disease interventions," Health Care Management Science, Springer, vol. 9(4), pages 311-324, November.
- William Weintraub & Samuel Gidding, 2016. "PCSK9 Inhibitors: A Technology Worth Paying For?," PharmacoEconomics, Springer, vol. 34(3), pages 217-220, March.
- James E. Smith & Ralph L. Keeney, 2005. "Your Money or Your Life: A Prescriptive Model for Health, Safety, and Consumption Decisions," Management Science, INFORMS, vol. 51(9), pages 1309-1325, September.
- Amy O’Sullivan & Jaime Rubin & Joshua Nyambose & Andreas Kuznik & David Cohen & David Thompson, 2011. "Cost Estimation of Cardiovascular Disease Events in the US," PharmacoEconomics, Springer, vol. 29(8), pages 693-704, August.
- Uwe Siebert & Oguzhan Alagoz & Ahmed M. Bayoumi & Beate Jahn & Douglas K. Owens & David J. Cohen & Karen M. Kuntz, 2012. "State-Transition Modeling," Medical Decision Making, , vol. 32(5), pages 690-700, September.
- Ian Philips & Graham Clarke & David Watling, 2017. "A Fine Grained Hybrid Spatial Microsimulation Technique for Generating Detailed Synthetic Individuals from Multiple Data Sources: An Application To Walking And Cycling," International Journal of Microsimulation, International Microsimulation Association, vol. 10(1), pages 167-200.
- Uwe Siebert, 2003. "When should decision-analytic modeling be used in the economic evaluation of health care?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 4(3), pages 143-150, September.
- Peter Lindgren & Bengt Jönsson, 2012. "Cost–effectiveness of statins revisited: lessons learned about the value of innovation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(4), pages 445-450, August.
More about this item
Keywords
cardiovascular disease; modeling; cost-effectiveness; validation; microsimulation;All these keywords.
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:sae:medema:v:37:y:2017:i:7:p:802-814. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: SAGE Publications (email available below). General contact details of provider: .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.